treprostinil
treprostinil: developed by 1 company · 2 clinical trials tracked.
treprostinil evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could treprostinil → UTHR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| UNITED THERAPEUTICS Corp (UTHR) Pulmonary arterial hypertension (PAH) | Approved |
Clinical Trials (2)
Comprehensive O2 Transfer Analysis From the Lung to Mitochondria of Inhaled Treprostinil in Interstitial Lung Disease Pulmonary Hypertension
Primary endpoint: Cardiac Output Reserve (Qc)
A Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation
Primary endpoint: Serum creatinine (SCr)
Frequently asked questions
Who is developing treprostinil?
treprostinil is being developed by UNITED THERAPEUTICS Corp.
How many clinical trials involve treprostinil?
BioSniper tracks 2 clinical trials involving treprostinil.